<prompt> Anakinrais-TNF a antagonistIL 1 antagonistIL 2 antagonistIL 6 antagonist  <response>: Ans. is b i.e., IL 1 antagonist BIOLOGIC RESPONSE MODIFIER BRMs Several recombinant proteinsmonoclonal antibodies that bind and inhibit cytokines, especially TNFa or IL-1 have been used succesfully in autoimmune diseases like RA, IBD, psoriosis or scleroderma.A. TNF-a inhibitorsa. Etanercept It is a recombinant fusion protein of TNF - receptor and Fc portion of human IgG1 It is administered by S.C. injection.b. Infliximab It is a chimeral monoclonol antibody which binds and neutralizes TNF-a. It is given by i.v. route. It is indicated in RA, psoriotic arthritis, Crohns disease, Wegeners granulomatosis and sarcoidosis.c. Adalimumab This recombinant monoclonal anti-TNF antibody. It is administered by S.C. route.B. IL-1 antagonistAnakinra It is a recombinant human IL-1 receptor antagonist. It is less effective than TNF inhibitors. It is administered by S.C. route.C. T-cell costimulatory blockersAbatacept It is a fusion protein that combines the extracellular domain of the molecule CTLA4 CD 154 with the Fc portion of a human immunoglobulin. It interfere with the interactions between antigen presenting cells and T lymphocytes. Therefore, it affects early stages in the pathogenic cascade of event in RA.D. B-cell depletersRituximab B-cells are inflammatory cells with multiple functions in the immune response. The depletion of B cells has been shown to be effective in reducing signs and symptoms of RA and in slowing radiographic progression. Rituximab is a chimeric monoclonal antibody that binds to the CD20 molecule on the B cell surface leading to the removal of B cells from the circulation. 